KCP
ELOS

Kenmare Capital Partners’s Syneron Medical Ltd ELOS Stock Holding History

Kenmare Capital Partners’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-90,500
Closed -$991K – 24
2017
Q2 		$991K Sell
90,500
-298,677
-77% -$3.27M 1.19% 15
2017
Q1 		$4.11M Buy
389,177
+119,338
+44% +$1.15M 3.98% 10
2016
Q4 		$2.27M Buy
+269,839
New +$2.11M 1.72% 17

Other funds holding ELOS

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

Kenmare Capital Partners's ELOS Position: Q3 2017 in Review

Kenmare Capital Partners sold out of Syneron Medical Ltd (ELOS) in Q3 2017, closing a stake of 90,500 shares — an estimated $991K sold.

Kenmare Capital Partners first reported a position in ELOS in Q4 2016 and held it in 3 quarters. The position peaked at $4.11M in Q1 2017. 4 funds tracked by Wall St. Rank hold ELOS as of Q3 2017.

  • Kenmare Capital Partners reported no remaining Syneron Medical Ltd position as of Q3 2017 after selling out during the quarter.
  • Kenmare Capital Partners sold 90,500 Syneron Medical Ltd shares in Q3 2017, an estimated $991K.
  • Kenmare Capital Partners first reported a position in Syneron Medical Ltd in Q4 2016 and held it in 3 quarters.
  • Kenmare Capital Partners's Syneron Medical Ltd position peaked at $4.11M in Q1 2017.
  • 4 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q3 2017.

Based on Kenmare Capital Partners's 13F filing for Q3 2017, filed 14 Nov 2017.